title: Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.
abstract: In a recent expert meeting, Swedish recommendations for the treatment of HCV infection were updated. An interferon-free combination of direct-acting antiviral agents was recommended as the first line standard-of-care treatment for chronic HCV infection. Interferon-based therapy should be considered as a second line option after an individual benefit-risk assessment. Treatment is strongly recommended for HCV infected patients with bridging fibrosis or cirrhosis (Metavir stages F3-4), before and after liver transplantation, and in the presence of extra-hepatic manifestations. Additionally, patients with moderate liver fibrosis (stage F2) as well as women in need of in vitro fertilisation should be prioritised for therapeutic intervention. Treatment indications for people who inject drugs, children, chronic kidney disease and HIV co-infection are also discussed.
authors.affiliation: a Department of Infectious Medicine , Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
authors.forename: Martin
authors.initials: M
authors.lastname: Lagging
authors.affiliation: a Department of Infectious Medicine , Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.|b Swedish Reference Group for Antiviral Therapy (RAV) , Sweden.
authors.forename: Rune
authors.initials: R
authors.lastname: Wejstål
authors.affiliation: a Department of Infectious Medicine , Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
authors.forename: Gunnar
authors.initials: G
authors.lastname: Norkrans
authors.affiliation: c Medical Products Agency , Uppsala , Sweden.
authors.forename: Olle
authors.initials: O
authors.lastname: Karlström
authors.affiliation: d Department of Infectious Diseases , Karolinska University Hospital , Stockholm , Sweden.
authors.forename: Soo
authors.initials: S
authors.lastname: Aleman
authors.affiliation: d Department of Infectious Diseases , Karolinska University Hospital , Stockholm , Sweden.
authors.forename: Ola
authors.initials: O
authors.lastname: Weiland
authors.affiliation: e Transplant Institute, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
authors.forename: Maria
authors.initials: M
authors.lastname: Castedal
authors.affiliation: c Medical Products Agency , Uppsala , Sweden.
authors.forename: Filip
authors.initials: F
authors.lastname: Josephson
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000188:drug therapy / Q000628:therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D007223:Infant; D008297:Male; D013548:Sweden
keywords: DAA, people who inject drugs; HCV; HIV co-infection; Hepatitis C virus; children; chronic kidney disease; direct-acting antiviral agents; guidelines